Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) | Zendy

Justin A. Ezekowitz | Zendy; Yinggan Zheng | Zendy; Alain CohenSolal | Zendy; Vojtěch Melenovský | Zendy; Jorge Escobedo | Zendy; Javed Butler | Zendy; Adrian F. Hernandez | Zendy; Carolyn S.P. Lam | Zendy; Christopher M. O’Connor | Zendy; Burkert Pieske | Zendy; Piotr Ponikowski | Zendy; Adriaan A. Voors | Zendy; Christopher R. deFilippi | Zendy; Cynthia M. Westerhout | Zendy; Ciaran J. McMullan | Zendy; Lothar Roessig | Zendy; Paul W. Armstrong | Zendy

Open Access

Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)

Author(s) -

Justin A. Ezekowitz,

Yinggan Zheng,

Alain CohenSolal,

Vojtěch Melenovský,

Jorge Escobedo,

Javed Butler,

Adrian F. Hernandez,

Carolyn S.P. Lam,

Christopher M. O’Connor,

Burkert Pieske,

Piotr Ponikowski,

Adriaan A. Voors,

Christopher R. deFilippi,

Cynthia M. Westerhout,

Ciaran J. McMullan,

Lothar Roessig,

Paul W. Armstrong

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.121.056797

Subject(s) - medicine , anemia , hematocrit , hemoglobin , placebo , heart failure , adverse effect , randomization , anemia of chronic disease , surgery , randomized controlled trial , iron deficiency , pathology , alternative medicine

In the VICTORIA trial (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction), anemia occurred more often in patients treated with vericiguat (7.6%) than with placebo (5.7%). We explored the association between vericiguat, randomization hemoglobin, development of anemia, and whether the benefit of vericiguat related to baseline hemoglobin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research